Radical Cystectomy Versus Chemoradiation for Muscle-invasive Bladder Cancer: Impact of Treatment Facility and Sociodemographics

Anticancer Res. 2017 Oct;37(10):5603-5608. doi: 10.21873/anticanres.11994.

Abstract

Background: The present study sought to compare the differences in practice patterns, as well as clinical outcomes for patients with muscle-invasive bladder cancer undergoing treatment with either radical cystectomy (RC) or concurrent chemoradiaiton (CRT).

Patients and methods: The National Cancer Data Base (NCDB) was queried for patients diagnosed with T2/T3/T4aN0M0 bladder cancer, between 2004-2013, that received definitive treatment with either RC or CRT.

Results: 16,960 patients met the inclusion criteria; 1,450 (8.5%) underwent CRT, while 15,510 (91.5%) were treated with RC. Patients undergoing CRT were older, more likely to be female, African American, received treatment at an academic facility, and lived <20 miles of the treatment facility. CRT was associated with worse median OS (32.8 months vs. 36.1 months; p=0.0004).

Conclusion: Older patients are more likely to undergo bladder preservation therapy, while those living farther away from treatment facilities are less likely to under CRT.

Keywords: Bladder cancer; bladder preservation; chemoradiation; chemotherapy; cystectomy; radiation therapy.

Publication types

  • Comparative Study

MeSH terms

  • Age Factors
  • Aged
  • Catchment Area, Health
  • Chemoradiotherapy / adverse effects
  • Chemoradiotherapy / mortality
  • Chemoradiotherapy / trends*
  • Cystectomy / adverse effects
  • Cystectomy / mortality
  • Cystectomy / trends*
  • Databases, Factual
  • Female
  • Health Services Accessibility / trends*
  • Healthcare Disparities / trends*
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Oncologists / trends*
  • Practice Patterns, Physicians' / trends*
  • Proportional Hazards Models
  • Risk Factors
  • Socioeconomic Factors*
  • Time Factors
  • Treatment Outcome
  • United States
  • Urinary Bladder Neoplasms / mortality
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / therapy*